Pfizer Inc. (NYSE: PFE) is a Healthcare company,
ranked #4,616 of 6,774 companies globally and #2,357 of 4,000 in United States on PositoAI,
with a Positivity Score of 19,207.
Its market capitalisation is ₹16.37 lakh Cr ($173.38B), P/E ratio is 40.0 and P/B ratio is 2.04.
It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
P/B Ratio2.04
P/E Ratio40.0
D/E Ratio0.74
ROE5.01%
Owes vs Owns ?0.57× Moderate$0.57 owed for every $1 it owns · balance sheet Jun 2026
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products…
What is Pfizer Inc.'s P/E and P/B ratio?
Pfizer Inc. has a P/E ratio of 40.0 and a P/B ratio of 2.04.
What is Pfizer Inc.'s debt-to-equity ratio?
Pfizer Inc. has a debt-to-equity ratio of 0.74.
How much does Pfizer Inc. owe compared with what it owns?
Pfizer Inc. owes $0.57 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Pfizer Inc.'s Positivity rank?
Pfizer Inc. is ranked #4,616 of 6,774 companies globally and #2,357 of 4,000 in United States on PositoAI, with a Positivity Score of 19,207.
Does Pfizer Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Pfizer Inc..
Where can I read the latest news about Pfizer Inc.?
Recent headlines about Pfizer Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Pfizer Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Pfizer Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.
0 / 1000
🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.
Disclaimer —
PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.